标题:Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016)
作者:Zhan, Peng; Wang, Xueshun; Liu, Xinyong; Suzuki, Takayoshi
作者机构:[Zhan, Peng; Wang, Xueshun; Liu, Xinyong] Shandong Univ, Sch Pharmaceut Sci, Key Lab Chem Biol, Minist Educ,Dept Med Chem, 44 West Culture Rd, Jinan 2 更多
通讯作者:Suzuki, T
通讯作者地址:[Suzuki, T]Japan Sci & Technol Agcy JST, CREST, 4-1-8 Honcho, Kawaguchi, Saitama 3320012, Japan.
来源:RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY
出版年:2017
卷:12
期:1
页码:16-34
DOI:10.2174/1574892811666161101102842
关键词:Chelating; drug design; epigenetics; HDAC inhibitor; histone; acetylation; metalloprotein; patent; synthesis
摘要:Background: Many laboratories have made intensive efforts to develop potent, selective, and orally bioavailable HDAC inhibitors (HDACIs). Novel HDACIs are being developed with the objective of improving potency and selectivity against specific types of cancers or non-cancer diseases.; Objective: This updated patent review is an attempt to compile the work of various researchers of HDACIs from 2012 to mid 2016, and to enlighten and surprise both newcomers in this field and devoted medicinal chemists.; Method: According to the literature research and the writers' own research experience in the discovery of HDAC inhibitors.; Results: The inhibitors possessing new chemical scaffolds have attracted immense interest because they have the ability to improve HDAC isoform specificity and pharmaceutical properties. Focus is given to emerging medicinal chemistry principles and insights into the discovery and development of HDAC inhibitors.; Conclusion: The development of effective HDACIs is shifting from trial-and-error approaches to sophisticated strategies. Effective profiling technologies will continue to have important utility.
收录类别:SCOPUS;SCIE
WOS核心被引频次:4
Scopus被引频次:3
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85011067311&doi=10.2174%2f1574892811666161101102842&partnerID=40&md5=b015b88f2f9a98427101efcc2f819682
TOP